Clinical Trial: Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07808333) titled 'Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)' on Sept. 02.

Brief Summary: The goal of this clinical trial is to learn whether a high-dose vitamin B3 supplement called nicotinamide can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment. The main question it aims to answer is: Does adding nicotinamide to standard glaucoma therapy slow the rate of thinning of the inner retinal nerve cell layer (measured by a non-invasive eye scan) compared to standard therapy alone over 12 months?

Participants will be...